The EMA grants PRIME (PRIority MEdicines) designation to Krystal Biotech’s (NASDAQ:KRYS) KB103 (bercolagene telserpavec), a topical gene therapy for the treatment of dystrophic epidermolysis bullosa (DEB).
PRIME Designation allows for frequent and early interactions with the EMA aimed at supporting accelerated evaluation and approval.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.